The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects.
Electro-oculogram (including saccadic eye movements), auditory-evoked potentials and visual analogue scales for a subjective impression of effects were used to evaluate some pharmacodynamic properties of RS-8359. In the electro-oculogram, administration of central nervous system-stimulating drugs is expected to decrease latency and fixation time and to increase angular velocity. As no significant effect on these parameters was found after any dose of RS-8359, within the limitations of the methods used, it seems unlikely that any appreciable direct stimulation of the central nervous system occurs with this agent, and significant central nervous system side effects also seem unlikely. Moreover, the data on auditory-evoked potentials suggest that RS-8359 may improve cognitive performance, which is often impaired in major depressive disorders. However, the doses used in these studies were associated with nausea and vomiting, possibly caused by increased serotonergic activity secondary to monoamine oxidase A inhibition. The results indicate that RS-8359 has no apparent sedative liability, which should benefit patients who need to remain in work, to drive or to continue other activities requiring a normal level of alertness.